Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

By Mark E. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, Wei Li, N. Tung, A. Armstrong and 4 more. New England Journal of Medicine, 2017

1,569 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1df775c9ec8ba24c565e1f857c82d78fec3afb5a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Reis-Filho
2. C. Lord
3. Balázs Győrffy

In Oncology

1. J. Reis-Filho
2. M. Jorge Cardoso
3. Larry Norton
4. C. Lord
5. Balázs Győrffy
6. A. Damjanović
7. M. Nedeljković

In Pulmonary and Respiratory Medicine

1. Balázs Győrffy

Citations in the corpus

• OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019, methodology): “The efficacy of the oral poly(ADP ribose) polymerase (PARP) inhibitor olaparib in patients with a germline BRCAm and HER2negative metastatic breast cancer (mBC) was confirmed in the Phase III OlympiAD study, with a statistically significant benefit in progression-free survival compared with chemothe”
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, result): “02) in a subgroup analysis of predefined stratification subgroups,(75) lending further support to existing data for a PFS benefit with olaparib in the ITT population of the study.(76) The EMBRACA study(77) had a similar design to the OlympiAD study, comparing talazoparib with ChT monotherapy per phy”
• A decade of clinical development of PARP inhibitors in perspective (2019, background): “In 2017, results from a randomized phase III trial (OlympiAD) in HER2-negative, gBRCA1/2 mutation-associated, metastatic breast cancer comparing olaparib with physician’s treatment choice (capecitabine, eribulin, vinorelbine, or gemcitabine) were reported [36].”
• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018, methodology): “The OlympiAD trial [52] evaluated the role of the poly adenosine diphosphate ribose polymerase (PARP) inhibitor olaparib monotherapy in 302 patients with germline BRCA mutation and advanced ER-positive/HER2-negative or TNBC, who had received no more than two previous ChT regimens for metastatic dise”
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer (2021, background): “In recent years few new agents have been approved, including CDK4/6 inhibitors for the treatment of advanced ER positive patients [7] and PARP inhibitors for patients with germline BRCA mutation [8].”
• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “Phase III studies reported a significant improvement of PFS with poly ADP ribose polymerase inhibitors (PARPi) in patients with germline BRCA1/2-mutated metastatic breast cancer (mBC).(70,71) It is currently estimated that somatic multigene sequencing cannot substitute germline testing for BRCA1/2 s”
• Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “Recently, PARP inhibitors, olaparib and talazoparib were approved for use in HER2 negative, BRCA mutated, metastatic breast cancer pretreated with chemotherapy [205,206].”
• Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019, neutral): “(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”